Life Biosciences injects experimental cellular reprogramming drug into three glaucoma patients, reports no serious adverse events

Life Biosciences provided an update on its early‑stage glaucoma study involving its experimental cellular reprogramming therapy.

The company said three patients have each received a single intravitreal injection of the investigational drug. The administration was performed under the study protocol and the patients are being monitored for safety.

To date, the sponsor reported no serious adverse events related to the treatment, indicating an acceptable safety profile in this small cohort. Further data will be needed to assess efficacy and longer‑term outcomes.